Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

VHT is attractively valued at 16x forward earnings, but sector momentum is weak and technicals remain bearish. Read why VHT ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Novo Nordisk has reported another significant criticality: the presence of unauthorized versions of its drugs on the US ...

The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

People taking weight loss drugs typically start to lose weight within a few weeks. One study, funded by Mounjaro manufacturer ...